Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Skin Neoplasms 2Sarcoma, Kaposi 2Sarcoma 2Melanoma 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumor, Pleural 1Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms, Plasma Cell 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Kidney Neoplasms 1Head and Neck Neoplasms 1HIV Infections 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Colonic Neoplasms 1Acquired Immunodeficiency Syndrome 1AIDS-related Kaposi sarcoma 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × Semaxinib × Clear all
NCT00017316 2013-02-11

Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
35 enrolled
Dermatologic

Melanoma

NCT00006003 2013-01-24

SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated

National Cancer Institute (NCI)

Phase 2 Terminated
35 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡